Celldex Therapeutics Inc. (CLDX)

2.37
NASDAQ : Health Technology
Prev Close 2.40
Day Low/High 2.33 / 2.40
52 Wk Low/High 2.01 / 11.62
Avg Volume 135.70K
Exchange NASDAQ
Shares Outstanding 15.02M
Market Cap 36.04M
EPS -14.50
P/E Ratio N/A
Div & Yield N.A. (N.A)
Celldex Therapeutics (CLDX): Today's Weak On High Volume Stock

Celldex Therapeutics (CLDX): Today's Weak On High Volume Stock

Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a weak on high relative volume candidate

Great Breadth Fails to Counter Boring Market

This, despite a rare 10-point jump in bulls in the Investors Intelligence readings, which usually occurs in bear markets.

6 Breakout Stocks Under $10 Set to Soar

6 Breakout Stocks Under $10 Set to Soar

These stocks trading for less than $10 a share are within range of triggering breakout trades.

Commit To Buy Celldex Therapeutics At $3, Earn 30% Using Options

Commit To Buy Celldex Therapeutics At $3, Earn 30% Using Options

Investors eyeing a purchase of Celldex Therapeutics, Inc. shares, but tentative about paying the going market price of $4.21/share, might benefit from considering selling puts among the alternative strategies at their disposal.

Celldex Therapeutics (CLDX) Is Today's Strong On High Volume Stock

Celldex Therapeutics (CLDX) Is Today's Strong On High Volume Stock

Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a strong on high relative volume candidate

Trade-Ideas: Celldex Therapeutics (CLDX) Is Today's "Perilous Reversal" Stock

Trade-Ideas: Celldex Therapeutics (CLDX) Is Today's "Perilous Reversal" Stock

Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a "perilous reversal" (up big yesterday but down big today) candidate

Celldex Therapeutics (CLDX) Weak On High Volume

Celldex Therapeutics (CLDX) Weak On High Volume

Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a weak on high relative volume candidate

Short Interest In Celldex Therapeutics Increases 12%

Short Interest In Celldex Therapeutics Increases 12%

The most recent short interest data has been released by the NASDAQ for the 03/31/2016 settlement date, which shows a 2,772,151 share increase in total short interest for Celldex Therapeutics, Inc. , to 25,763,736, an increase of 12.06% since 03/15/2016.

Anavex Plays the Orphan Drug Stock Promotion Game

Anavex Plays the Orphan Drug Stock Promotion Game

Too many investors have a fundamental misunderstanding about the significance of orphan drug designation. I should say, insignificance, because the FDA delineation, on its own, means very little.

Trade-Ideas: Celldex Therapeutics (CLDX) Is Today's "Perilous Reversal" Stock

Trade-Ideas: Celldex Therapeutics (CLDX) Is Today's "Perilous Reversal" Stock

Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a "perilous reversal" (up big yesterday but down big today) candidate

Trade-Ideas: Celldex Therapeutics (CLDX) Is Today's Strong On High Relative Volume Stock

Trade-Ideas: Celldex Therapeutics (CLDX) Is Today's Strong On High Relative Volume Stock

Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a strong on high relative volume candidate

7 Stocks Under $10 to Trade for Breakout Gains

7 Stocks Under $10 to Trade for Breakout Gains

These stocks trading for less than $10 a share are within range of triggering big breakout trades.

Celldex Therapeutics (CLDX) Highlighted As Today's Perilous Reversal Stock

Celldex Therapeutics (CLDX) Highlighted As Today's Perilous Reversal Stock

Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a "perilous reversal" (up big yesterday but down big today) candidate

6 Biotech Stocks Under $10 to Trade for Big Breakouts

6 Biotech Stocks Under $10 to Trade for Big Breakouts

These stocks trading for less than $10 a share are within range of triggering big breakout trades.

Biotech Stock Mailbag: Biomarin PKU Preview, Celldex Post-Mortem

Biotech Stock Mailbag: Biomarin PKU Preview, Celldex Post-Mortem

TheStreet's Senior Columnist Adam Feuerstein answers reader questions about biotech stocks.

Trade-Ideas: Celldex Therapeutics (CLDX) Is Today's Weak On High Relative Volume Stock

Trade-Ideas: Celldex Therapeutics (CLDX) Is Today's Weak On High Relative Volume Stock

Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a weak on high relative volume candidate

Today's Dead Cat Bounce Stock Is Celldex Therapeutics (CLDX)

Today's Dead Cat Bounce Stock Is Celldex Therapeutics (CLDX)

Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a "dead cat bounce" (down big yesterday but up big today) candidate

Celldex Therapeutics (CLDX) Stock Downgraded at Jefferies

Celldex Therapeutics (CLDX) Stock Downgraded at Jefferies

Jefferies downgraded Celldex Therapeutics (CLDX) stock and cut its price target to $4 from $31.

3 Stocks Pushing The Health Care Sector Lower

3 Stocks Pushing The Health Care Sector Lower

TheStreet highlights 3 stocks pushing the health care sector lower today.

Here's Why Celldex (CLDX) Stock is Plunging Today

Here's Why Celldex (CLDX) Stock is Plunging Today

Celldex (CLDX) stock is plummeting in early-morning trading on Monday after an independent board recommended the company discontinue its Phase 3 trial for a treatment for glioblastoma.

Heavy Trading On Celldex Therapeutics (CLDX) Before Market Open

Heavy Trading On Celldex Therapeutics (CLDX) Before Market Open

Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a pre-market mover with heavy volume candidate

Celldex Brain Tumor Vaccine Fails Pivotal Clinical Trial

Celldex Brain Tumor Vaccine Fails Pivotal Clinical Trial

There's bad news from Celldex Therapeutics on Monday. The pivotal brain tumor clinical trial involving the company's experimental cancer vaccine Rintega was halted for futility.

TheStreet Quant Rating: D- (Sell)